Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its ...

Novartis’ anti-IgE antibody Xolair (omalizumab) has been a mainstay of treatment for refractory CSU for many years. However, ...

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular ...

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in ...

Approval by the European Commission generally follows a few weeks after a CHMP decision, and that situation contrasts with ...

At the ASCO congress in Chicago today, the results of the ASC4FIRST trial of Scemblix (asciminib) in people recently ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial ...

The FDA sent the Japanese pharma a complete response letter (CRL) in January saying it was unable to approve zolbetuximab as ...

The US Senate has joined the House of Representatives in approving the first-ever federal bill dedicated to ending ...

The FDA previously approved the drug to treat RET-positive thyroid cancer in adults and children aged 12 years of age and ...

The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the ...

J&J is also developing a second potential blockbuster for MDD, selective kappa opioid receptor (KOR) antagonist aticaprant, ...